Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TAK-169 |
Trade Name | |
Synonyms | TAK169|TAK 169|MT-0169|MT0169|MT 0169 |
Drug Descriptions |
TAK-169 is an engineered toxin body comprising a fragment of a CD38 antibody fused to Shiga-like toxin A-subunit (SLTA) that inactivates ribosomes, which potentially inhibits protein synthesis leading to killing of CD38-expressing cancer cells and tumor regression (Cancer Res 2019;79(13 Suppl):Abstract nr 2384). |
DrugClasses | CD38 Antibody 20 |
CAS Registry Number | NA |
NCIT ID | C173707 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
TAK-169 | TAK-169 | 0 | 2 |